Artificial intelligence remains the most impactful technology shaping the pharmaceutical industry, with companies increasingly integrating it into research, development and commercialization, according to GlobalData. The company says AI is becoming central as drugmakers seek efficiencies, cost reductions and better patient outcomes.
In the latest GlobalData report, The State of the Biopharmaceutical Industry 202674% of respondents identified AI as the most disruptive emerging technology in the industry. The analysis suggests strong momentum behind the adoption of AI as part of broader digital transformation strategies.
Wafaa Hassan, senior strategic intelligence analyst at GlobalData, said the appeal of AI lies in its ability to accelerate drug discovery, reduce R&D costs and improve prediction of patient outcomes. She noted that analyzing complex, large-scale data sets allows AI to surface insights that might otherwise go unnoticed.